XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 12 - Subsequent Event
6 Months Ended
Jun. 30, 2016
Notes to Financial Statements  
Subsequent Events [Text Block]
12.          Subsequent Event
 
 
In August 2016, the Board of Directors determined that RES-440, a “soft” anti-androgen compound for the treatment of acne vulgaris, was outside the Company’s core product focus, is not a priority and therefore will be abandoned and written off in the third quarter of 2016. The abandonment will result in a $932,000 charge to earnings to reduce the carrying amount of the RES-440 IPR&D asset and will also result in a reduction of the associated deferred tax liability.